DarioHealth Q1 Earnings Call Highlights

1 hour ago 1

MarketBeat

Wed, May 13, 2026 astatine 10:05 AM CDT 7 min read

DarioHealth logo

Key Points

Interested successful DarioHealth Corp.? Here are 5 stocks we similar better.
DarioHealth posted sequential gross growth for the 2nd consecutive quarter, with Q1 gross rising to $5.6 cardinal from $5.2 cardinal successful Q4 2025. Operating losses and expenses besides improved twelvemonth implicit year, portion the institution ended the 4th with $20 cardinal successful currency and deposits.
Channel partnerships are driving growth: much than 80% of gross present comes from partner-driven channels, and DarioHealth added 10 caller accounts successful Q1. Management said its pipeline was astir $127 cardinal crossed 241 unfastened opportunities, with respective larger accounts expected to motorboat aboriginal successful 2026.
The institution is expanding beyond integer engagement into attraction transportation and outcomes-based models by partnering with objective providers and wellness systems. DarioHealth besides highlighted its AI engine, DarioIQ, and said it remains progressive successful a strategical reappraisal that could see a sale, merger, oregon continued standalone execution.

DarioHealth is an AI-Powered Digital Therapeutics Play

DarioHealth (NASDAQ:DRIO) reported sequential gross maturation for the 2nd consecutive 4th portion outlining plans to grow its integer wellness level further into attraction delivery, absorption said connected the company’s first-quarter 2026 net telephone Wednesday.

Chief Executive Officer Erez Raphael said the institution entered 2026 with “continued momentum,” citing gross growth, reduced operating expenses and advancement converting 2025 commercialized wins into revenue. Management besides highlighted a increasing transmission spouse strategy, caller relationship additions and plans to usage DarioHealth’s information and artificial quality capabilities to enactment much outcomes-based and claims-related models.

Revenue Rises Sequentially arsenic Costs Decline

→ MercadoLibre Boldly Invests successful Growth: Discount Deepens

In the company’s fiscal review, absorption said first-quarter gross was $5.6 million, up from $5.2 cardinal successful the 4th fourth of 2025. The institution said the year-over-year gross diminution from the archetypal 4th of 2025 reflected a planned determination distant from non-recurring pharmaceutical gross that is not portion of its halfway concern model.

Gross borderline was 57% successful the archetypal quarter, astir level from a twelvemonth earlier and up from 54% successful the 4th quarter. Management said DarioHealth’s B2B2C non-GAAP gross borderline remained astir 80% for the ninth consecutive quarter, which it described arsenic an important operator of operating leverage arsenic that gross basal grows.

→ Rocket Lab Just Hit a New All-Time High—Time to Buy oregon Let It Breathe?

Total operating expenses were $10.5 million, down 21% year-over-year and 8% sequentially. Non-GAAP operating expenses were $8.7 million, down 18% from the anterior twelvemonth and 3% from the 4th fourth of 2025. Operating nonaccomplishment was $7.3 million, improving 22% year-over-year and 15% sequentially. Non-GAAP operating nonaccomplishment was $5.3 million.

Read Entire Article